<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918424</url>
  </required_header>
  <id_info>
    <org_study_id>804P303</org_study_id>
    <nct_id>NCT00918424</nct_id>
  </id_info>
  <brief_title>Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects</brief_title>
  <official_title>Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      Follow-on study to continue evaluation of the safety of OXC XR as adjunctive therapy in
      pediatric epilepsy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients with partial onset epilepsy enrolled in a pharmacokinetic study of OXC XR
      were allowed to continue treatment with the investigational drug in this extensión study. The
      primary interest was in assessing the safety of treatment with OXC XR over a period of
      months.
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <start_date>June 2009</start_date>
  <study_type>Expanded Access</study_type>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine Extended Release</intervention_name>
    <description>OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.</description>
    <other_name>Oxtellar XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed assent (IAF), as appropriate, with written informed
             permission (and informed consent (ICF) where required by regional laws or regulations)
             from the parent or legally-authorized representative (LAR).

          2. Was eligible for and completed the 804P107 study.

          3. Weight within the 25 - 75 % weight-for-age percentiles based on the National Center
             for Health Statistics Growth Charts, and not less than 15.0kg, when entering the
             804P107 study.

          4. Able and willing to swallow whole tablets.

          5. Females of childbearing potential (FOCP) should either be sexually inactive
             (abstinent) for 14 days prior to entering the 804P107 804P107, throughout this study,
             and for four days following the last dose; or, if sexually active, will be using one
             of the following acceptable birth control methods:

               1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy) six months minimum;

               2. Intrauterine device in place for at least three months;

               3. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to
                  the first dose of the 804P107 study, throughout the study, and for four days
                  following the last dose;

               4. Surgical sterilization of the partner (vasectomy for six months minimum);

               5. Hormonal contraceptives in addition to a barrier method (condom, diaphragm) with
                  spermicide for at least 14 days prior to the first dose of the 804P107 study,
                  throughout the study, and for four days following the last dose.

        Exclusion Criteria:

          1. Meets criteria for history of major depressive or manic episode, according to
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.

          2. Any history of suicide intent and/or attempt.

          3. History or presence of clinically significant, chronic medical condition, especially
             those contraindicating antiseizure medication, (e.g., any neurological,
             gastrointestinal, endocrine, cardiovascular, pulmonary, hematological, immunologic,
             renal, hepatic or metabolic disease) that may affect the safety of the subject in the
             opinion of the Investigator.

          4. Use of felbamate with less than 18 months of continuous exposure prior to screening
             for the 804P107 study and continuous use throughout this study.

          5. Frequent need of rescue benzodiazepines (more than once in a 28 day period).

          6. Use of diuretics or other sodium-lowering medications.

          7. History or presence of clinically significant laboratory, electrocardiogram (ECG), or
             vital sign abnormalities that may affect the safety of the subject, in the opinion of
             the Investigator at the end of study visit for the 804P107 study.

          8. Presence of potential hepatic function impairment as shown by, but not limited to,
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times the upper
             limit of normal (ULN), or total bilirubin &gt;1.5 times ULN, according to the lab results
             of the 804P107 study.

          9. Presence of suspected impairment of renal function defined by serum creatinine ≥1.5
             times ULN, according to the lab results of the 804P107 study.

         10. Females who are pregnant or lactating.

         11. Previous known hypersensitivity to OXC or other related drugs, such as carbamazepine.

         12. Any reason which, in the opinion of the Investigator, would prevent the subject from
             participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

